14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Mon, 20 May 2024

Trading levels for PBYI

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 5.27 28.73 %
R2 4.93 20.43 %
R1 4.72 15.30 %
Current price: 4.10
Support S1 4.04 -1.30 %
S2 3.83 -6.43 %
S3 3.49 -14.73 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 4.70 14.65 %
R2 4.66 13.80 %
R1 4.30 5.01 %
Current price 4.10
Support S1 0 .
S2 0 .
S3 0 .

PBYI Predictions History

5 years ago
David.Tran.100193 predicted that PBYI for 2019-03-06 is going $42.00 (8.75%)

Rank:

6 years ago
bbullish2 predicted that PBYI for 2018-02-02 is going $65.11 (-0.60%)

6 years ago
Metallica predicted that PBYI for 2018-02-02 is going $66.92 (2.17%)

Rank:

6 years ago
JS predicted that PBYI for 2017-11-14 is going $101.66 (1.46%)

6 years ago
JuanC Villegas predicted that PBYI for 2017-11-14 is going $103.45 (3.24%)

6 years ago
Naveen.reddy.14010 predicted that PBYI for 2017-11-14 is going $100.49 (-0.60%)

Rank:

6 years ago
michael.schanding.10551 predicted that PBYI for 2017-11-14 is going $101.49 (0.39%)

Rank:

7 years ago
JS predicted that PBYI for 2016-08-25 is going $56.80 (-0.26%)

7 years ago
kevin predicted that PBYI for 2016-08-25 is going $46.92 (-18.92%)

Rank:

7 years ago
Stockdum predicted that PBYI for 2016-08-08 is going $47.99 (-0.62%)

Click to get the best stock tips daily for free!

About Puma Biotechnology Inc

Puma Biotechnology Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advance... PBYI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT